Axa S.A. Has $1.11 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Axa S.A. decreased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 2.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 36,764 shares of the company’s stock after selling 856 shares during the period. Axa S.A. owned about 0.06% of Harmony Biosciences worth $1,109,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Squarepoint Ops LLC acquired a new stake in Harmony Biosciences in the 2nd quarter valued at $1,509,000. Marshall Wace LLP raised its stake in Harmony Biosciences by 145.4% during the second quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock worth $9,220,000 after acquiring an additional 181,092 shares in the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of Harmony Biosciences by 2.9% during the second quarter. Public Sector Pension Investment Board now owns 70,020 shares of the company’s stock valued at $2,113,000 after acquiring an additional 1,955 shares during the period. Profund Advisors LLC boosted its stake in shares of Harmony Biosciences by 11.1% in the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company’s stock valued at $228,000 after purchasing an additional 758 shares in the last quarter. Finally, Pacer Advisors Inc. grew its holdings in shares of Harmony Biosciences by 0.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,509,609 shares of the company’s stock worth $75,715,000 after purchasing an additional 14,695 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Stock Performance

HRMY stock opened at $39.24 on Wednesday. The stock has a market capitalization of $2.23 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 0.77 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.13 and a quick ratio of 3.09. The company has a 50 day moving average price of $35.86 and a 200 day moving average price of $32.60. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $40.60.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.24. The business had revenue of $172.80 million for the quarter, compared to analyst estimates of $172.53 million. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.56 earnings per share. Analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current year.

Analysts Set New Price Targets

HRMY has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research report on Tuesday, September 24th. Citigroup assumed coverage on Harmony Biosciences in a report on Friday, June 21st. They issued a “buy” rating and a $48.00 target price on the stock. Finally, UBS Group initiated coverage on Harmony Biosciences in a report on Tuesday, September 10th. They set a “buy” rating and a $56.00 price target for the company. Two equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat, Harmony Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.